Effects of Roux-en-Y gastric bypass on fasting and postprandial levels of the inflammatory markers YKL-40 and MCP-1 in patients with type 2 diabetes and glucose tolerant subjects

Journal of Obesity

Volumn 2013, Issue , 2013, Pages

  Thomsen, Stine Brinkløv ^a   Rathcke, Camilla Noelle ^b   Jørgensen, Nils Bruun ^a,c,d   Madsbad, Sten ^e   Vestergaard, Henrik ^a  

^a Novo Nordisk Foundation   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AMAGER HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C PEPTIDE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; YKL 40 PROTEIN; ADIPOCYTOKINE; CCL2 PROTEIN, HUMAN; CHI3L1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; GLUCOSE TOLERANCE; HUMAN; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY MASS; COMPARATIVE STUDY; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; MORBID OBESITY; POSTOPERATIVE PERIOD; STOMACH BYPASS; TIME; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GASTRIC BYPASS; GLUCOSE; HUMANS; INSULIN RESISTANCE; LECTINS; MALE; MIDDLE AGED; OBESITY, MORBID; POSTOPERATIVE PERIOD; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84888884552     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2013/361781     Document Type: Article

References (42)

1. Pradhan A. D., Skerrett P. J., Manson J. E., Obesity, diabetes, and coronary risk in women. Journal of Cardiovascular Risk 2002 9 6 323 330 2-s2.0-0036927451 10.1097/00043798-200212000-00005 (Pubitemid 36044386)
2. Mathieu P., Poirier P., Pibarot P., Lemieux I., Després J.-P., Visceral obesity the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009 53 4 577 584 2-s2.0-64849088450 10.1161/ HYPERTENSIONAHA.108.110320
3. Despres J. P., Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012 126 1301 1313
4. Cancello R., Clément K., Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. British Journal of Obstetrics and Gynaecology 2006 113 10 1141 1147 2-s2.0-33748742519 10.1111/j.1471-0528.2006.01004.x (Pubitemid 44401207)
5. Pickup J. C., Inflammatory markers and type 2 diabetes. Diabetes Technology and Therapeutics 2006 8 1 1 6 2-s2.0-33645319007 10.1089/dia.2006.8.1
6. Laugerette F., Vors C., Géloën A., Chauvin M.-A., Soulage C., Lambert-Porcheron S., Peretti N., Alligier M., Burcelin R., Laville M., Vidal H., Michalski M.-C., Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. Journal of Nutritional Biochemistry 2011 22 1 53 59 2-s2.0-78649978620 10.1016/j.jnutbio.2009.11.011
7. Chow J. C., Young D. W., Golenbock D. T., Christ W. J., Gusovsky F., Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. Journal of Biological Chemistry 1999 274 16 10689 10692 2-s2.0-0033574415 10.1074/jbc.274.16.10689 (Pubitemid 29191043)
8. Cani P. D., Amar J., Iglesias M. A., Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007 56 1761 1772 (Pubitemid 47025442)
9. Hedegaard A., Sejersten Ripa R., Johansen J. S., Jørgensen E., Kastrup J., Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation 2010 70 2 80 86 2-s2.0-77949817816 10.3109/00365510903518191
10. Nøjgaard C., Høst N. B., Christensen I. J., Poulsen S. H., Egstrup K., Price P. A., Johansen J. S., Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coronary Artery Disease 2008 19 4 257 263 2-s2.0-54749135440 10.1097/MCA.0b013e3282f40dd5
11. Kucur M., Isman F. K., Karadag B., Vural V. A., Tavsanoglu S., Serum YKL-40 levels in patients with coronary artery disease. Coronary Artery Disease 2007 18 5 391 396 2-s2.0-34547531506 10.1097/MCA.0b013e328241d991 (Pubitemid 47186840)
12. Nielsen A. R., Erikstrup C., Johansen J. S., Fischer C. P., Plomgaard P., Krogh-Madsen R., Taudorf S., Lindegaard B., Pedersen B. K., Plasma YKL-40 A BMI-independent marker of type 2 diabetes. Diabetes 2008 57 11 3078 3082 2-s2.0-58149352840 10.2337/db08-0182
13. Rathcke C. N., Johansen J. S., Vestergaard H., YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflammation Research 2006 55 2 53 59 2-s2.0-33645815907 10.1007/s00011-005-0010-8
14. Hempen M., Kopp H.-P., Elhenicky M., Höbaus C., Brix J.-M., Koppensteiner R., Schernthaner G., Schernthaner G.-H., YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obesity Surgery 2009 19 11 1557 1563 2-s2.0-70449523003 10.1007/s11695-009-9917-4
15. Catalán V., Gómez-Ambrosi J., Rodríguez A., Ramírez B., Rotellar F., Valentí V., Silva C., Gil M. J., Salvador J., Frühbeck G., Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. Journal of Clinical Endocrinology and Metabolism 2011 96 1 200 209 2-s2.0-78650917241 10.1210/jc.2010-0994
16. Mygind N. D., Harutyunyan M. J., Mathiasen A. B., Ripa R. S., Thune J. J., Gøtze J. P., Johansen J. S., Kastrup J., The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflammation Research 2011 60 3 281 287 2-s2.0-79951723231 10.1007/s00011-010-0266-5
17. Yadav A., Saini V., Arora S., MCP-1: chemoattractant with a role beyond immunity: a review. Clinica Chimica Acta 2010 411 21-22 1570 1579 2-s2.0-79955784400 10.1016/j.cca.2010.07.006
18. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K.-I., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M., MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation 2006 116 6 1494 1505 2-s2.0-33745216724 10.1172/JCI26498
19. Yla-Herttuala S., Lipton B. A., Rosenfeld M. E., Sarkioja T., Yoshimura T., Leonard E. J., Witztum J. L., Steinberg D., Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proceedings of the National Academy of Sciences of the United States of America 1991 88 12 5252 5256 2-s2.0-0025954705 10.1073/pnas.88.12.5252 (Pubitemid 21914722)
20. Buchwald H., Estok R., Fahrbach K., Banel D., Jensen M. D., Pories W. J., Bantle J. P., Sledge I., Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. American Journal of Medicine 2009 122 3 248 256 2-s2.0-61549094077 10.1016/j.amjmed.2008.09.041
21. Schauer P. R., Kashyap S. R., Wolski K., Brethauer S. A., Kirwan J. P., Pothier C. E., Thomas S., Abood B., Nissen S. E., Bhatt D. L., Bariatric surgery versus intensive medical therapy in obese patients with diabetes. New England Journal of Medicine 2012 366 17 1567 1576 2-s2.0-84860136615 10.1056/NEJMoa1200225
22. Mingrone G., Panunzi S., De Gaetano A., Guidone C., Iaconelli A., Leccesi L., Nanni G., Pomp A., Castagneto M., Ghirlanda G., Rubino F., Bariatric surgery versus conventional medical therapy for type 2 diabetes. New England Journal of Medicine 2012 366 17 1577 1585 2-s2.0-84859419232 10.1056/NEJMoa1200111
23. Jorgensen N. B., Jacobsen S. H., Dirksen C., Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. American Journal of Physiology: Endocrinology and Metabolism 2012 303 E122 E131
24. Dunn J. P., Abumrad N. N., Breitman I., Marks-Shulman P. A., Flynn C. R., Jabbour K., Feurer I. D., Tamboli R. A., Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy. Diabetes Care 2012 35 1 137 142 2-s2.0-84859041004 10.2337/dc11-1383
25. Camastra S., Gastaldelli A., Mari A., Bonuccelli S., Scartabelli G., Frascerra S., Baldi S., Nannipieri M., Rebelos E., Anselmino M., Muscelli E., Ferrannini E., Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 2011 54 8 2093 2102 2-s2.0-79960913296 10.1007/s00125-011-2193-6
26. Miller G. D., Nicklas B. J., Fernandez A., Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surgery for Obesity and Related Diseases 2011 7 5 618 624 2-s2.0-80053328335 10.1016/j.soard.2011.03.006
27. Monte S. V., Caruana J. A., Ghanim H., Sia C. L., Korzeniewski K., Schentag J. J., Dandona P., Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 2012 151 4 587 593 2-s2.0-84858439217 10.1016/j.surg.2011.09.038
28. Schernthaner G.-H., Kopp H.-P., Kriwanek S., Krzyzanowska K., Satler M., Koppensteiner R., Schernthaner G., Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte- chemoattractant-protein-1 in morbid obesity. Obesity Surgery 2006 16 6 709 715 2-s2.0-33646674384 10.1381/096089206777346763 (Pubitemid 43874824)
29. Johansen J. S., Lottenburger T., Nielsen H. J., Jensen J. E. B., Svendsen M. N., Kollerup G., Christensen I. J., Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiology Biomarkers and Prevention 2008 17 10 2603 2608 2-s2.0-54249128937 10.1158/1055-9965.EPI-07-2766
30. Thomsen S. B., Rathcke C. N., Skaaby T., Linneberg A., Vestergaard H., The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population. PLoS ONE 2012 7 e47094
31. Rathcke C. N., Vestergaard H., YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovascular Diabetology 2009 8, article 61 2-s2.0-71949101822 10.1186/1475-2840-8-61
32. Kastrup J., Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012 217 5 483 491 2-s2.0-84858797734 10.1016/j.imbio.2011.04.007
33. Lumeng C. N., Saltiel A. R., Inflammatory links between obesity and metabolic disease. Journal of Clinical Investigation 2011 121 6 2111 2117 2-s2.0-79957920754 10.1172/JCI57132
34. Neiken N. A., Coughlin S. R., Gordon D., Wilcox J. N., Monocyte chemoattractant protein-1 in human atheromatous plaques. Journal of Clinical Investigation 1991 88 4 1121 1127 2-s2.0-0026075699
35. De Lemos J. A., Morrow D. A., Sabatine M. S., Murphy S. A., Gibson C. M., Antman E. M., McCabe C. H., Cannon C. P., Braunwald E., Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003 107 5 690 695 2-s2.0-0037432168 10.1161/01.CIR.0000049742.68848.99 (Pubitemid 36222595)
36. Mariani E., Cattini L., Neri S., Malavolta M., Mocchegiani E., Ravaglia G., Facchini A., Simultaneous evaluation of circulating chemokine and cytokine profiles in elderly subjects by multiplex technology: relationship with zinc status. Biogerontology 2006 7 5-6 449 459 2-s2.0-34548499454
37. Rull A., Camps J., Alonso-Villaverde C., Joven J., Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (orCCL2) in the regulation of metabolism. Mediators of Inflammation 2010 2010 11 2-s2.0-78349279253 10.1155/2010/326580 326580
38. Michelsen A. E., Rathcke C. N., Skjelland M., Holm S., Ranheim T., Krohg-Sørensen K., Klingvall M. F., Brosstad F., Øie E., Vestergaard H., Aukrust P., Halvorsen B., Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 2010 211 2 589 595 2-s2.0-77955275761 10.1016/j.atherosclerosis.2010.02.035
39. Zhang H., DiBaise J. K., Zuccolo A., Kudrna D., Braidotti M., Yu Y., Parameswaran P., Crowell M. D., Wing R., Rittmann B. E., Krajmalnik-Brown R., Human gut microbiota in obesity and after gastric bypass. Proceedings of the National Academy of Sciences of the United States of America 2009 106 7 2365 2370 2-s2.0-60549086580 10.1073/pnas.0812600106
40. Ghanim H., Abuaysheh S., Sia C. L., Korzeniewski K., Chaudhuri A., Fernandez-Real J. M., Dandona P., Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009 32 12 2281 2287 2-s2.0-72249106180 10.2337/dc09-0979
41. Kjaergaard A. D., Bojesen S. E., Johansen J. S., Nordestgaard B. G., Elevated plasma YKL-40 levels and ischemic stroke in the general population. Annals of Neurology 2010 68 5 672 680 2-s2.0-78249263495 10.1002/ana.22220
42. Létuvé S., Kozhich A., Arouche N., Grandsaigne M., Reed J., Dombret M.-C., Kiener P. A., Aubier M., Coyle A. J., Pretolani M., YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. Journal of Immunology 2008 181 7 5167 5173 2-s2.0-58149308830